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Abstract “Mutational signatures” are patterns of mutations that report DNA damage and
subsequent repair processes that have occurred. Whole-genome sequencing (WGS) can
provide additional information to standard diagnostic techniques and can identify thera-
peutic targets. A 32-yr-old male with xeroderma pigmentosum developed metastatic
angiosarcoma that was unresponsive to three lines of conventional sarcoma therapies.
WGSwas performed on his primary cancer revealing a hypermutated tumor, including clon-
al ultraviolet radiation-inducedmutational patterns (Signature 7) and subclonal signatures of
mutated DNA polymerase epsilon (POLE) (Signature 10). These signatures are associated
with response to immune checkpoint blockade. Immunohistochemistry confirmed high
PD-L1 expression in metastatic deposits. The anti-PD-1 monoclonal antibody pembrolizu-
mab was commenced off-label given the POLE mutation and high mutational load. After
four cycles, there was a significant reduction in his disease with almost complete resolution
of the metastatic deposits. This case highlights the importance of WGS in the analysis, in-
terpretation, and treatment of cancers. We anticipate that as WGS becomes integral to
the cancer diagnostic pathway, treatments will be stratified to the individual based on their
unique genomic and/or transcriptomic profile, enhancing classical approaches of histolog-
ically driven treatment decisions.
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INTRODUCTION
Xeroderma pigmentosum (XP) is a rare, autosomal recessive disorder of nucleotide excision
repair (NER), with an incidence in Western Europe of 2–3 per million live births (Kleijer et al.
2008). There are eight different complementation groups, dependent on the XP protein that
is mutated (XP-A through G and V). The XP-A to G proteins are involved in repairing bulky
DNA damage caused by ultraviolet radiation (UVR)—namely, cyclobutane pyrimidine dimers
(CPDs) and 6–4 pyrimidine-pyrimidone photoproducts (Brash 2015). Unrepaired CPDs cause
a UVR-related mutational signature characterized by C>T and CC>TT substitutions (Brash
2015). As a result of the excess of UVR-related damage, patients develop exposed-site pig-
mentary changes, multiple skin cancers, and ocular surface disease and one-third of patients
develop progressive neurodegeneration (Fassihi et al. 2016). XP patients have a 2000-fold
increased incidence of melanoma, and a 10,000-fold increased incidence of non-melanoma
skin cancer (Bradford et al. 2011).
The immune system plays a critical role in the surveillance of malignant cells. However, its
effectiveness can be restricted by various immune-escape or checkpoint mechanisms. In par-
ticular, the programmed death protein (PD-1) binds to ligands PD-L1 and PD-L2. Upon activa-
tion, T cells express PD-1, which interacts with PD-L1 on tumor and stromal cells, deactivating
the T cells and negatively regulating T-cell effector functions (Gentzler et al. 2016).
Immune checkpoint inhibitors interfere with these checkpoints, reactivating antitumor
activity of cytotoxic T cells. Immunotherapies like anti-PD-1 and anti-PD-L1 have revolution-
ized the treatment of certain malignancies, especially melanoma (Gentzler et al. 2016). Their
role in treating other solid organ malignancies is expanding (Gentzler et al. 2016). Higher tu-
mor PD-L1 levels may be an indicator of an enhanced response to treatment. However, the
role of PD-L1 as a predictive biomarker is controversial, as there is a subset of PD-L1 negative
tumors that still respond to PD-1/PD-L1 inhibition (Gentzler et al. 2016). Tumors with high
mutational loads have been shown to demonstrate a greater response to immune check-
point blockade (Howitt et al. 2015). One explanation for this is the creation of a large number
of neoantigens. Nevertheless, other factors are likely to play a role, as not all hypermutated
tumors respond in the same way (Howitt et al. 2015).
Somatic mutations in the proofreading exonuclease domain of DNA polymerase epsilon
(POLE) have been associated with tumors of high mutational loads (Shinbrot et al. 2014).
Mutations in POLE have been reported in colorectal and 10% of endometrial cancers
(Gargiulo et al. 2016). In a study of hypermutated endometrial cancers (>232×10−6 muta-
tions/Mb), tumors with somatic POLEmutations were associated with a 15-fold higher num-
ber of neoepitopes per sample when compared to tumors with microsatellite instability
(MSI). POLE-mutated and MSI tumors also had a higher number of CD3+ (P=0.001) and
CD8+ (P<0.001) tumor-infiltrating lymphocytes (TILs) compared to microsatellite-stable tu-
mors. POLE mutations are associated with increased PD-1 and PD-L1 expression (Howitt
et al. 2015). PD-1 was shown to be overexpressed in TILs and peritumoral lymphocytes of
POLE-mutated tumors, thus suggesting that POLE-mutated tumors may be candidates for
PD-1/PD-L1-targeted immunotherapies (Howitt et al. 2015). POLE mutations have been
demonstrated in an extensive number of tumor types that have shown sensitivity to check-
point inhibitors (Gargiulo et al. 2016).
RESULTS
Case
A 32-yr-old Caucasian male with XP complementation group C (compound heterozygous
mutations; c.445_446delGA in exon 4a and c.2336 del T in exon 13 in XPC) (XP1SH)
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presented in January 2017 with a rapidly growing violaceous nodule on the left supraorbital
area (Fig. 1). He had a history of multiple non-melanoma skin cancers. Histopathology dem-
onstrated a dense dermal infiltrate of pale, eosinophilic, neoplastic cells extending from the
papillary to the reticular dermis. These cells “dissected the collagen bundles” and had en-
larged and hyperchromatic nuclei (Fig. 2A,B). Immunostaining was positive for vascular
markers CD31 and ERG (Fig. 2C,D). The neoplastic cells were negative for S100, CD34,
and MFT 116. All these findings were in keeping with the diagnosis of cutaneous angiosar-
coma. Positron emission tomography–computed tomography (PET-CT) showed no meta-
static disease. A wide local excision was undertaken at the regional sarcoma unit, and
clear margins were reported. Adjuvant radiotherapy was not given. Eight months later, he
presented with a right submandibular palpable mass; fine-needle aspiration confirmed met-
astatic angiosarcoma. A repeat PET-CT showed bilateral submandibular nodes. Hewas com-
menced on ifosfamide and doxorubicin at a standard dosing, which was well-tolerated. After
six cycles, a PET-CT showed metastatic disease in the lung and liver. Eighteen months after
diagnosis he was enrolled into the TAPPAS trial of TRC105 (carotuximab, a monoclonal an-
tibody targeting CD105) and pazopanib versus pazopanib alone. After 1 month there was
suspicion of clinical disease progression, and upon repeat imaging, further metastatic
disease was confirmed, with mediastinal, pericardial, pleural, liver, and bony infiltration
(Fig. 3). A base-of-skull metastasis demonstrated direct cranial extension. His Eastern
Collaborative Oncology Group-Performance Status (ECOG-PS) was 3 and he was admitted
as an inpatient with severe cachexia, anorexia, and concerns about imminent terminal com-
plications of his disease. Bilateral pneumothoraces were treated with video-assisted thoracic
surgery (VATS) procedures and pleurodeses. Palliative radiotherapy 36Gy in 12 fractions was
given to a mandibular tumor deposit because of impending tracheal compression (Fig. 4).
WGS was performed on a primary tumor biopsy (Fig. 5).
Genomic Analysis
Driver mutations were identified in TP53 (H179Y, variant allele fraction of 26%) andCDKN2A
(homozygous whole-gene deletion). Driver mutations linked to angiogenesis previously
Figure 1. Clinical image of patient highlighting angiosarcoma on the medial aspect of his left eyebrow.
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reported in angiosarcomas, PTPRB and PLCG1, were not observed (Behjati et al. 2014).
Mutations in TP53 and homozygous deletions of CDKN2A have previously been reported
in angiosarcomas (Behjati et al. 2014). WGS additionally revealed an extremely high muta-
tional load of 805,261 substitutions and 1007 small insertions/deletions (indels) (Fig. 5).
Two base substitutionmutational signatures were identified. Signature 7, the classic “UV sig-
nature” (Alexandrov et al. 2013) comprising C>T transitions and CC>TT double substitu-
tions accounted for 91.2% of these. This is the mutational signature that is commonly
seen in melanoma (Pleasance et al. 2010). In a patient with deficient NER, this signature
would be expected, even in noncancerous “normal” skin. However, Signature 10 was also
identified, accounting for a small fraction of 8.8% of themutational load in the primary tumor.
This signature is characterized by three distinctive substitution peaks—C>A substitutions at
TCT trinucleotides, C>T substitutions at TCG trinucleotides and T>G substitutions at TTT
trinucleotides—and is reported in association with activating driver mutations in the proof-
reading exonuclease domain of POLE (Cancer Genome Atlas Network 2012). The possibility
that this mutation was present in a subclone of the primary tumor was raised. Closer inspec-
tion revealed a subclonal driver mutation in POLE (S459F, variant allele fraction of 17%).
Although it is a noncanonical POLE mutation, it maps to the Exo III motif of the endonucle-
ase. Functional work supports reduced proofreading activity of an expression construct car-
rying this mutation, supporting driver potential, and it is this mutation that was driving the
patient’s metastatic disease (Shinbrot et al. 2014).
Both a high mutational burden and somatic mutations in POLE are reported to be pre-
dictors of sensitivity to immune checkpoint inhibitors. Consistent with this prediction, immu-
nohistochemistry of PD-L1 was positive on both the primary excision and on a metastatic
lymph node deposit (60% positivity) (Fig. 6). However, anti-PD-/PD-L1 therapy for angiosar-
coma is not currently licensed given the lack of clinical trial data supporting its use (Table 1).
Figure 2. (A,B) Hematoxylin and eosin staining of skin biopsy shows dermal infiltrate of pale eosinophilic cells
that have characteristic features of “dissecting the collagen bundles” and atypical, enlarged, and hyperchro-
matic nuclei. (C,D) Immunostaining shows staining for vascular markers CD31 and ERG (labeled).
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Treatment Outcomes
The anti-PD-1 monoclonal antibody pembrolizumab at 200 mg every 3 weeks was com-
menced off-label given the POLE mutation and high mutational load. Treatment was toler-
ated well with no side effects. After four cycles there was evidence of resolution of the lung
and bone disease and almost complete resolution of the cardiac disease and pericardial ef-
fusions. There was significant reduction in the liver metastases and the residual visible liver
disease was no longer FDG-avid (Fig. 3). Activity remained in a soft tissue jawmass and pleu-
ral tissue; however, these were significantly reduced in volume (Fig. 4). The remaining jaw
uptake is suggestive of osteoradionecrosis and may not represent ongoing malignant dis-
ease. His weight has increased from 48 kg to 56 kg and ECOG-PS is 0. Diuretics, high
dose steroids, and opiates have been weaned completely. He has now had 11 cycles, he
is back at work full-time, and treatment is ongoing.
DISCUSSION
Angiosarcoma and XP
Cutaneous angiosarcomas are rare malignancies of endothelial cells that often occur on the
head and neck of the elderly (Griffiths et al. 1998). They arise spontaneously or secondary to
ionizing radiation or chronic lymphoedema (Griffiths et al. 1998). Angiosarcoma has a poor
Figure 3. Figure showing response of disease after four cycles of pembrolizumab. Pretreatment CT image
(left) and PET-CT scan after four cycles of pembrolizumab (right). The top row shows a reduction in the size
of liver metastases; themiddle row shows a reduction in the size of lung metastatic deposits; and the bottom
row shows the mediastinal response.
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prognosis, and metastatic disease is common. It has an estimated mean 5-yr survival rate of
33.5% (Griffiths et al. 1998). Genomic studies of angiosarcomas have identified key driver
mutations in genes linked to angiogenesis (Behjati et al. 2014). Truncating mutations in
PTPRB (an endothelial phosphatase and negative regulator of vascular growth factor tyrosine
kinases) and activating Arg707Gln missense mutations in PLCG1 (a signal transducer of ty-
rosine kinase) have been reported (Behjati et al. 2014).
These mutations were not present in our case. Angiosarcoma is rarely seen in the context
of XP; there are 11 reports of angiosarcoma in XP patients, with most of these (n=10) occur-
ring on the head and neck (Leake et al. 1992; De Silva et al. 1999; Ludolph-Hauser et al.
2000; Marcon et al. 2004; Arora et al. 2008; Olson et al. 2012; Sharma et al. 2012;
Karkouche et al. 2013). Of these, seven patients were treated with surgical excision, three
with surgery plus radiotherapy, and one with chemotherapy. Only two patients had local re-
currence, and no metastatic disease was observed over a mean follow-up period of 1–40
months. Chemotherapy and radiotherapy can be used in patients with XP in most cases,
but specialist advice is suggested. Anti-PD-L1 inhibition has been successfully used for
the treatment of metastatic melanoma and metastatic cutaneous squamous cell carcinomas
in patients with XP (Deinlein et al. 2017; Salomon et al. 2018).
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Figure 4. Circos plot of whole-genome sequenced angiosarcoma. It depicts a chromosomal ideogram on the
outermost ring. Moving inward, the next ring shows a large number of C>T transitions. The next ring depicts
small (<100-bp) insertions (green) and deletions (red). Then the next rings report copy-number state (green=
gains, pink= losses), and the lines in the center of the plot report structural variants, of which there are not
many. The right-hand top panel displays the substitution mutation profile. This graph shows that there are
805,261 C>T transitions with a mutational profile that is typical of UV damage. The right-hand middle panel
shows the distribution of classes of indels, of which there are 1007. The right-hand bottom panel shows the
types of structural variants that are present in this tumor.
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Angiosarcoma and Its Treatment
Cutaneous angiosarcoma is managed with surgical excision of the primary tumor, with or
without postoperative radiotherapy. Chemotherapy with doxorubicin or paclitaxel has
been used for metastatic disease, and based on data from retrospective and prospective tri-
als, its true value is unclear. Sindhu et al. (2017) report a patient with metastatic angiosar-
coma expressing PD-L1, treated with off-label pembrolizumab 2 mg/kg every 21 d for 13
cycles with shrinkage of his liver disease and no new facial lesions during an 8-mo follow-
up period off treatment. To date, there are no immunotherapy agents licensed to treat
angiosarcoma. Furthermore, secondary autoimmune-related complications have been re-
ported with checkpoint inhibitor therapy. This is the first report of a patient with end-stage
metastatic angiosarcoma on the background of XP being treated with immunotherapy.
Figure 5. Clinical images showing large soft tissue mass on left jaw that was causing tracheal compression
(A) and post three cycles of pembrolizumab (B).
Figure 6. Immunohistochemistry performed on primary excision staining positive for PD-L1 (60%).
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CONCLUSION
In the last decade, whole-genome sequencing has enabled us to visualize every mutation
present in a human cancer genome, allowing us to gain insights into the drivers and muta-
tional signatures present in an individual’s cancer. Mutational signatures can offer unique in-
sights into the pathogenesis of a cancer and provide information that may be translated into
possible therapeutic and preventative treatments (Nik-Zainal et al. 2016). In this case, muta-
tional signatures from WGS have been used as a biomarker to guide immunotherapy. Our
patient had none of the classical “drivers” seen in an angiosarcoma, possibly explaining
why he progressed after three lines of “standard” treatment. The histological appearances
were a poor predictor of treatment response, whereas the molecular fingerprint was an ex-
cellent predictor of response to therapy with pembrolizumab. We hope that as WGS be-
comes an integral part of cancer care, cancer treatments will be stratified to the individual
based on their uniquemutational makeup as opposed to the classical method of histological
based treatment decisions. Because formal clinical trials are not possible in ultra-rare situa-
tions such as this one, mutational fingerprinting in individual cases and small patient cohorts
will be critical in providing effective therapies to these patients.
METHODS
Immunohistochemistry
Immunohistochemistry was performed and positive for the vascular markers CD31 and ERG.
Negative markers included S100, CD34, and MFT 116.
Table 1. Genomic analysis of the patient’s primary angiosarcoma
Gene Chromosome Genomic location
HGVS DNA
reference
HGVS
protein
reference Variant type
Predicted
effect
dbSNP/
dbVar ID Genotype
POLE 12 g.133249847G>A c.1376C>T p.S459F Sub Missense Heterozygous
TP53 17 g.7578395 G>A c.535C>T p.H179Y Sub Missense rs587780070 Heterozygous
CDKN2A 9 g. 21694602–
23444942
Homozygous
deletion
Whole gene
deletion
Homozygous
Table 2. Table showing quality control metrics for whole-genome sequencing
Sequence metrics Sequencing method Whole-genome sequencing
Tumor coverage 35.6×
Normal coverage 31.09×
Additional text Duplicate read rate < 10%
Processing Alignment BWA v2.0.54
Substitutions CaVEMan v1.11.2
Indels Pindel v2.2.2
Rearrangements Brass v5.4.1
Copy number ASCAT (NGS) v4.0.1
Raw data Substitutions 805,261
Indels 1007
Rearrangements 11
Ploidy 1.85
Aberrant cell fraction 0.35
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Genomic sequencing
WGS was performed on genomic DNA from the original tumor and peripheral blood lym-
phocyes, using Illumina HiSeq X TEN, 150-bp paired-end sequencing technology.
Average tumor coverage was 35.6× and average normal coverage was 31.09× (Table 2).
Short reads were aligned to build GRCh37 using BWA v2.0.54, substitutions called using
CaVEMan v1.11.2, indels called using Pindel v2.2.2, structural variation called using Brass
v5.4.1, and copy number using ASCAT (NGS) v4.0.1. Total ploidy was estimated to be 1.85.
ADDITIONAL INFORMATION
Data Deposition and Access
The raw sequencing data has been submitted to the European Genome-phenome Archive
(EGA) (https://ega-archive.org/) under accession number EGAD00001004786. The variants
have been uploaded to Mendeley and can be found under doi number: 10.17632/
7cxt72pckw.1 (https://data.mendeley.com/datasets/7cxt72pckw/1).
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